Research on adherence to protein kinase inhibitor treatment in patients with chronic myeloid leukaemia (CML) revealed the existence of a strong relationship between the missing of only a small number of doses per month (5%) and a less favourable clinical outcome [9]. Here, WEE1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.